Agendia Presents Broad Spectrum of Data from FLEX Study Highlighting Tumor Heterogeneity within Underrepresented or Underserved Patient Populations at SABCS 2020
Agendia, Inc., a world leader in precision oncology for breast cancer, today announced that data from FLEX, the large-scale, prospective, observational breast cancer study, has been selected for presentation in six posters during the 2020 San Antonio Breast Cancer Symposium (SABCS 2020). The posters, being presented at different sessions throughout SABCS 2020, focus on underrepresented or underserved populations or types of breast cancer.
“FLEX could be one of the most valuable, impactful, flexible, and inclusive studies in breast cancer research to date,” said Laura Lee, M.D., Surgical Oncology Specialist at Desert Comprehensive Breast Center at Desert Regional Medical Center, and first author of the FLEX update poster. “These data reveal that tumor heterogeneity goes beyond ethnicities and underscores the importance of gene expression analysis as a tool for bringing those differences to light. We are enrolling patients representing all of the clinical and genomic subtypes from a broad spectrum of community and academic sites. As researchers, we are excited by the opportunity to access this real-world data set where we can ask meaningful clinical questions and then see what the data tell us.”
Highlights from the FLEX data are as follows:
- [OT12-01] The FLEX real-world data platform explores new gene expression profiles and investigator-initiated protocols in early stage breast cancer outlines updates from the FLEX study, a registry intended to enable the discovery of novel genomic profiles to improve precision in the management of breast cancer. With purposefully-wide inclusion criteria, the registry aims to enable researchers to investigate the differences and trends between breast cancer subgroups and allow focus on smaller, more diverse patient populations, which have traditionally been challenging to recruit in sufficient numbers for clinical trials.
- [PS7-69] Molecular profiles and clinical-pathologic features of Asian early-stage breast cancer patients assesses the clinical, pathological and molecular profiles from self-reported Asian breast cancer patients (AS), in comparison with age-matched Caucasian (CA) and African American patients (AA), to evaluate the influence of Asian ancestry on differential gene expression in breast tumors. The analysis revealed different gene set enrichment patterns in tumors of AS compared with CA and AA, which may contribute to differential clinical outcomes and highlights the importance of including patients of Asian ancestry in genomic breast cancer research. Additionally, the poster found more differentially-expressed genes in MammaPrint High Risk tumors between AS and AA patients than between AS and CA patients, reinforcing the need for additional research to evaluate the influence of ancestry on differential gene expression in breast tumors.
- [PS14-11] Differential gene expression analysis and clinical utility of MammaPrint and BluePrint in male breast cancer patients compares the under-researched population of male breast cancer patients (MaBC) to that of female breast cancer patients (FBC) to determine whether significant molecular biological differences exist between the two groups. Utilizing the MammaPrint and BluePrint assays, the analysis suggests that distinct biological pathways between the two groups indicate an upregulation of estrogen response and MTORC1 signaling in MaBC compared to FBC, and warrants further investigation to assess clinical outcomes.
- [PS7-68] Racial disparities within Basal-type breast cancer: clinical and molecular features of African American (AA) and Caucasian (CA) obese patients investigates differential gene expression between two ethnic groups with clinically-matched comorbidities, in this case diabetes and obesity, who have been diagnosed with Basal-type breast cancer. The goal is to determine the influence metabolic factors or patient ancestry may have on outcomes as these data mature. Currently, the analysis suggests that there are further disparities in AA and CA patients beyond those attributable to clinical and social factors, which may help identify novel treatment approaches in the future.
- [PS18-03] Differential gene expression in Luminal-Type invasive lobular carcinoma and invasive ductal carcinoma by MammaPrint risk stratification assesses differential gene expression between invasive lobular carcinomas (ILC) and invasive ductal carcinomas (IDC) in a large, age-matched patient subset using MammaPrint and BluePrint to stratify those populations. The analysis suggests that when evaluated by MammaPrint, about one-third of ILCs were classified as MammaPrint High Risk, displaying heterogeneity in High Risk tumors and MammaPrint’s ability to predict unfavorable survival outcomes for patients with this type of tumor. The study results underscore the ability of FLEX to enroll smaller patient populations on a larger scale, enabling further investigation and the opportunity to provide targets for treatment optimization for those patients.
- [PS18-05] Using BluePrint to elucidate the molecular heterogeneity of triple negative breast cancers assesses triple negative breast cancers (TNBC) to understand the relationship between gene expression signatures provided by BluePrint and immunohistochemistry-defined TNBC. The analysis suggests that BluePrint enables further stratification of TNBC tumors, moving this type of cancer into different subgroups and shedding new light on TNBC tumor heterogeneity that may one day impact treatment planning.
“TNBC has long been a difficult diagnosis for both patients and physicians because of its aggressive nature. Very often, there is no time and no room for trial and error in the treatment decision-making process so there is a lot of pressure to get things right,” said Virginia Kaklamani, M.D., Co-director of SABCS, leader of the Breast Cancer Program at UT Health San Antonio MD Anderson Cancer Center, Professor of Medicine in the Division of Hematology/Oncology at UT Health San Antonio, and first author on the poster focusing on TNBC tumors. “By leveraging BluePrint for the evaluation and stratification of TNBC tumors, we hope to be able to tease out the differences in this challenging type of cancer – which can sometimes include more than one activated genomic pathway – to determine where and when to hit it hardest for the benefit of our patients.”
These data are part of a large suite of 13 posters, spotlight sessions and an oral presentation on MammaPrint and BluePrint that were accepted to SABCS 2020, and underscore Agendia’s mission to help guide the diagnosis and personalized treatment of breast cancer for all patients throughout their treatment journey.
Agendia is a precision oncology company headquartered in Irvine, California, committed to bringing early stage breast cancer patients and their physicians the information they need to make the best decisions for the full treatment journey. The company currently offers two commercially-available genomic profiling tests, supported by the highest levels of clinical and real world evidence, that provide comprehensive genomic information that can be used to identify the most effective breast cancer treatment possible for each patient.
MammaPrint®, the 70-gene breast cancer recurrence assay, is the only FDA-cleared risk of recurrence test backed by peer-reviewed, prospective outcome data and inclusion in both national and international treatment guidelines. BluePrint®, the 80-gene molecular subtyping assay, is the only commercially-available test that evaluates the underlying biology of a tumor to determine what is driving its growth. Together, MammaPrint® and BluePrint® provide a comprehensive genomic profile to help physicians make more informed decisions in the pre- and post-operative treatment settings.
Agendia develops evidence-based novel genomic tests and forges partnerships with groundbreaking companies to develop next-generation digital treatment tools. The ongoing research builds an arsenal of data that improve patient outcomes and support the evolving clinical needs of breast cancer patients and their physicians every step of the way, from initial diagnosis to cancer-free.
Agendia’s assays can be ordered on core biopsies or surgical specimens to inform pre- and post-operative treatment decisions. For more information on Agendia’s assays and ongoing trials, please visit www.agendia.com.
Westwicke/ICR Healthcare PR
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Takeda Named Global Top Employer for Fourth Consecutive Year25.1.2021 03:00:00 EET | Press release
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that it is one of only 16 companies to achieve global Top Employer® certification for 2021. In addition to receiving the global certification for the fourth consecutive year, Takeda was also certified as a Top Employer in four regions and 38 countries. This underscores the company’s commitment to creating an exceptional people experience for its global workforce. For more than 30 years, Top Employers Institute has given annual award certification to companies with outstanding culture, work environments, benefits and opportunities for their people. The Institute certifies organizations based on the results of its HR Best Practices Survey. The survey covers 20 people-centric topic areas, including Career Development, Culture, Diversity & Inclusion, Learning, Sustainability, Values, Well-being and Work Environment. “We are very proud of the global, regional and country recognition we’ve received from Top
GPD Companies, Inc. to Acquire Distrupol22.1.2021 16:33:00 EET | Press release
GPD Companies, Inc., an affiliate of One Rock Capital Partners, LLC (“One Rock”), today announced that it has entered into a definitive agreement to acquire Distrupol, a subsidiary of Univar Solutions Inc. (NYSE: UNVR) and a leading European distributor of thermoplastics to the polymer processing industry. Terms of the transaction, which is expected to close in the first half of 2021, were not disclosed. Headquartered in Surrey, England, with broad geographic reach across Europe, Distrupol has provided value-added sales and application development of thermoplastic resins for over 50 years. Through its decades-long relationships with world class supply partners, the company offers a robust array of superior performance products and solutions that meet the needs of diverse end users from leading and emerging industries, such as the consumer, medical, automotive, and electrical sectors, among others. Distrupol caters to over 1,300 customers across 13 countries with a portfolio of over 4,0
Schlumberger Announces Fourth-Quarter and Full-Year 2020 Results22.1.2021 14:50:00 EET | Press release
Schlumberger Limited (NYSE: SLB) today reported results for the fourth-quarter and full-year 2020. Fourth-Quarter Results (Stated in millions, except per share amounts) Three Months Ended Change Dec. 31, 2020 Sept. 30, 2020 Dec. 31, 2019 Sequential Year-on-year Revenue $5,532 $5,258 $8,228 5% -33% Income (loss) before taxes - GAAP basis $471 $(54) $452 n/m 4% Net income (loss) - GAAP basis $374 $(82) $333 n/m 12% Diluted EPS (loss per share) - GAAP basis $0.27 $(0.06) $0.24 n/m 12% Adjusted EBITDA* $1,112 $1,018 $1,648 9% -33% Adjusted EBITDA margin* 20.1% 19.4% 20.0% 73 bps 6 bps Pretax segment operating income* $654 $575 $1,006 14% -35% Pretax segment operating margin* 11.8% 10.9% 12.2% 90 bps -40 bps Net income, excluding charges & credits* $309 $228 $545 35% -43% Diluted EPS, excluding charges & credits* $0.22 $0.16 $0.39 37% -44% Revenue by Geography International $4,343 $4,210 $5,834 3% -26% North America 1,167 1,034 2,339 13% -50% Other 22 14 55 n/m n/m $5,532 $5,258 $8,228 5% -
JEOL: Release of a New Cold Field Emission Cryo-Electron Microscope CRYO ARM™ 300 II (JEM-3300)22.1.2021 09:00:00 EET | Press release
JEOL Ltd. (TOKYO:6951) (President & COO Izumi Oi) announces the release of a new cold field emission cryo-electron microscope (cryo-EM), the CRYO ARM™ 300 II (JEM-3300), to be released in January 2021. This new cryo-EM has been developed based on the concept of "Quick and easy to operate and get high-contrast and high-resolution images". This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210121005316/en/ Cold Field Emission Cryo-Electron Microscope CRYO ARM(TM) 300 II (JEM-3300) (Photo: Business Wire) Development Background Recent dramatic improvement of resolution in single particle analysis (SPA) using cryo-EM has led to SPA as an essential method for structural analysis of proteins. To address this market, JEOL released the CRYO ARM™ 300 in 2017. Equipped with a cold field emission gun (Cold FEG) for enhanced resolution and a cryo-stage for loading multiple samples, the CRYO ARM™ 300 has continued to achieve best-in-class res
ViiV Healthcare announces FDA approval of Cabenuva (cabotegravir, rilpivirine), the first and only complete long-acting regimen for HIV treatment22.1.2021 01:12:00 EET | Press release
ViiV Healthcare, the global specialist HIV company majority owned by GlaxoSmithKline plc (“GSK”), with Pfizer Inc. and Shionogi Limited as shareholders, today announced that the US Food and Drug Administration (FDA) approved Cabenuva, the first and only complete long-acting regimen for the treatment of HIV-1 infection in adults. Cabenuva is provided as a co-pack with two injectable medicines — ViiV Healthcare’s cabotegravir and Janssen’s rilpivirine — dosed once monthly, as an option to replace the current antiretroviral (ARV) regimen in those who are virologically suppressed (HIV-1 RNA less than 50 copies per milliliter [mL]) on a stable regimen, with no history of treatment failure, and with no known or suspected resistance to either cabotegravir or rilpivirine. Prior to initiating treatment of Cabenuva, oral dosing of cabotegravir and rilpivirine should be administered for approximately one month to assess the tolerability of each therapy.1 Lynn Baxter, Head of North America, ViiV H
Incyte Announces Acceptance and Priority Review of BLA for Retifanlimab as a Potential Treatment for Patients with Squamous Cell Carcinoma of the Anal Canal (SCAC)22.1.2021 00:30:00 EET | Press release
Incyte (Nasdaq:INCY) today announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review its Biologics License Application (BLA) for retifanlimab, an intravenous PD-1 inhibitor, as a potential treatment for adult patients with locally advanced or metastatic squamous cell carcinoma of the anal canal (SCAC) who have progressed on, or who are intolerant of, platinum-based chemotherapy. The BLA submission is based on data from the Phase 2 POD1UM-202 trial evaluating retifanlimab in previously treated patients with locally advanced or metastatic SCAC who have progressed on, or are intolerant of, standard platinum-based chemotherapy. The trial enrolled 94 patients, including several with well-controlled human immunodeficiency virus (HIV) infection. The study, which was recently presented at the European Society for Medical Oncology (ESMO) Virtual Congress 2020, resulted in an objective response rate (ORR) of 14% for retifanlimab monotherapy as determined by inde
Wistron and Kalray Announce FURIO1200™ Storage Appliance21.1.2021 19:45:00 EET | Press release
Wistron, a leader in ICT (Information and communications technology) products, and Kalray (Paris:ALKAL) (Euronext Growth Paris: ALKAL), a leading provider in new generation of processors specialized in Intelligent Data Processing from Cloud to Edge, announce the availability of FURIO1200™, a 24-Flash-Drive NVMe-oF based storage node appliance, integrating Kalray’s NVMe-oF K200™ smart storage adapter, powered by its MPPA® Coolidge™ intelligent processor, and Wistron LYMMA chassis. FURIO1200™ is a new type of hyper-fast disaggregated storage solution delivering ultra-high throughput and reliability. It is the ideal solution for Cloud Service Providers and Enterprises running applications with intensive AI and Data Analytics workloads as well as to optimize their next generation storage. Data Centers are undergoing a very important revolution due to the explosion of usages, the surge of data to be processed and the exponential growth of the number of machines to be managed to support this
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom